natgillin/translations-raw huggingface dataset:
Rasilamlo can be used with other antihypertensive medicines, with the exception of ‘angiotensin converting enzyme (ACE) inhibitors' or ‘angiotensin receptor blockers' (ARBs) in patients with diabetes, or moderate or severe kidney impairment. 
Zdravilo Rasilamlo se lahko uporablja sočasno z drugimi zdravili za zdravljenje hipertenzije z izjemo zaviralcev angiotenzinske konvertaze (ACE) ali zaviralcev angiotenzinskih receptorjev (ARB) pri bolnikih s sladkorno boleznijo oziroma zmerno ali hudo okvaro ledvic.
In the first study, patients taking Rasilamlo 300/10 mg and 300/5 mg had a fall in their sitting diastolic blood pressure of 13.1 mmHg and 10.5 mmHg, respectively, compared with a fall of 5.8 mmHg in patients taking aliskiren 300 mg. 
V prvi študiji se je pri bolnikih, ki so jemali zdravilo Rasilamlo v odmerku 300/10 mg oz. 300/5 mg, diastolični krvni tlak v sedečem položaju znižal za 13,1 mmHg oz. 10,5 mmHg v primerjavi z znižanjem za 5,8 mmHg pri bolnikih, ki so jemali 300 mg aliskirena.
Rasilamlo was more effective at controlling essential hypertension than placebo, aliskiren or amlodipine used alone. 
Zdravilo Rasilamlo je bilo pri uravnavanju esencialne hipertenzije učinkovitejše od placeba, aliskirena ali amlodipina kot samostojnih zdravil.
Rasilamlo is a medicine that contains the active substances aliskiren and amlodipine. 
Rasilamlo je zdravilo, ki vsebuje zdravilni učinkovini aliskiren in amlodipin.
It blocks the activity of a human enzyme called renin, which is involved in the production of a substance called angiotensin I in the body. 
Zavira dejavnost človeškega encima, imenovanega renin, ki v telesu sodeluje pri tvorjenju angiotenzina I. Angiotenzin I se pretvori v hormon angiotenzin II, ki deluje kot močan vazokonstriktor (učinkovina, ki oži žile).
The third study showed a fall in blood pressure of 8.5 mmHg with Rasilamlo 150/5 mg compared with 8.0 mmHg and 4.8 mmHg with amlodipine 10 mg and 5 mg, respectively. 
V tretji študiji se je pri jemanju zdravila Rasilamlo v odmerku 150/5 mg krvni tlak znižal za 8,5 mmHg v primerjavi z 8,0 mmHg oz. 4,8 mmHg pri jemanju amlodipina v odmerku 10 mg oz. 5 mg.
Rasilamlo contains two active substances, aliskiren and amlodipine. 
Zdravilo Rasilamlo vsebuje dve zdravilni učinkovini, aliskiren in amlodipin.
What is Rasilamlo used for? 
Za kaj se zdravilo Rasilamlo uporablja?
In the second study the falls in blood pressure were 11.0 mmHg and 9.0 mmHg with Rasilamlo 300/10 mg and 150/10mg, respectively, compared with 7.2mmHg with amlodipine 10 mg. 
V drugi študiji se je pri jemanju zdravila Rasilamlo v odmerku 300/10 mg oz. 150/10 mg krvni tlak znižal za 11,0 mmHg oz. 9,0 mmHg v primerjavi z znižanjem za 7,2 mmHg pri jemanju 10 mg amlodipina.
Rasilamlo in combination with an ACE inhibitor or an ARB must not be used in patients with diabetes, or moderate or severe kidney impairment. 
Zdravilo Rasilamlo se v kombinaciji z zaviralcem angiotenzinske konvertaze ali zaviralcem angiotenzinskih receptorjev ne sme uporabljati pri bolnikih s sladkorno boleznijo oziroma zmerno ali hudo okvaro ledvic.
How is Rasilamlo used? 
Kako se zdravilo Rasilamlo uporablja?
How does Rasilamlo work? 
Kako zdravilo Rasilamlo deluje?
Not known (frequency cannot be estimated from the available data) 
Pogostnost neznana (pogostnosti iz razpoložljivih podatkov ni mogoče oceniti)
If renal dysfunction is observed, appropriate management and treatment should be prescribed in accordance with standard treatment guidelines. 
Če se ugotovi ledvična disfunkcija, je treba predpisati ustrezno obvladovanje in zdravljenje skladno s standardnimi smernicami.
OTHER SPECIAL WARNING(S), IF NECESSARY Use only as directed by a doctor. 
DRUGA POSEBNA OPOZORILA, ČE SO POTREBNA Uporabljajte samo po zdravnikovih navodilih.
For CML, your doctor may prescribe a higher or lower dose depending on how you respond to the treatment. 
Pri zdravljenju KML vam lahko zdravnik predpiše večji ali manjši odmerek, odvisno od tega, kako se odzivate na zdravljenje.
If you have any questions about how Imatinib Accord works or why this medicine has been prescribed for you, ask your doctor. 
Če imate kakšna vprašanja glede tega, kako zdravilo Imatinib Accord deluje ali zakaj vam je bilo predpisano to zdravilo, vprašajte svojega zdravnika.
235 adult patients with accelerated phase disease were enrolled. 
Vključili so 235 odraslih bolnikov s pospešeno fazo bolezni.
Some children and adolescents taking Imatinib Accord may have slower than normal growth. 
Pri nekaterih otrocih in mladostnikih, ki jemljejo zdravilo Imatinib Accord, je lahko rast počasnejša od normalne.
Other adverse reactions were reported with lower or equal frequency. 
Pri drugih neželenih reakcijah so poročali o manjši ali enaki pogostosti.
Frequency categories are defined using the following convention: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000), not known (cannot be estimated from the available data). 
Kategorije pogostnosti so opredeljene z naslednjim dogovorom: zelo pogosti (≥1/10), pogosti (≥1/100 do <1/10), občasni (≥1/1.000 do <1/100), redki (≥1/10.000 do <1/1.000), zelo redki (<1/10.000), neznana (ni mogoče oceniti iz razpoložljivih podatkov).
The amount of Imatinib Accord given will depend on your child's condition, body weight and height. 
Potrebna količina zdravila Imatinib Accord bo odvisna od otrokovega stanja, telesne mase in višine.
Study ADE04 Prephase 
Študija ADE04 predhodna faza
• Do not use any pack that is damaged or shows signs of tampering. 
• Ne uporabite škatle, če je poškodovana ali kaže znake, da je bila že odprta.
In all clinical studies 38-40% of patients were > 60 years of age and 10-12% of patients were > 70 years of age. 
V vseh kliničnih študijah je bilo 38-40 % bolnikov starih  60 let, 10-12 % bolnikov pa je bilo starih  70 let.
If you are unable to swallow the tablets, you can dissolve them in a glass of still water or apple juice: 
Če tablet ne morete pogoltniti, jih lahko raztopite v kozarcu navadne vode ali jabolčnega soka:
Median age was 51 years (range 18-70 years), with 21.9% of patients ≥ 60 years of age. 
Povprečna starost je bila 51 let (razpon 18-70 let), 21,9 % bolnikov je bilo starih ≥ 60 let.
Patients should be instructed to use measures such as protective clothing and sunscreen with high sun protection factor (SPF). 
Bolnikom je treba naročiti, naj se poslužujejo ukrepov, kot so zaščita z oblačili in uporaba zaščitne kreme z visokim zaščitnim faktorjem (SPF - sun protection factor).
Date of first authorization: 01 July 2013 Date of latest renewal: 19th April 2018 
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Z ZDRAVILOM Datum prve pridobitve dovoljenja za promet: 1. julij 2013 Datum podaljšanja dovoljenja za promet: 19. april 2018
Ki values in human liver microsomes were 27, 7.5 and 7.9 mol/l, respectively. 
Vrednosti Ki v mikrosomih človeških jeter so bile 27, 7,5 oziroma 7,9 μmol/l.
Other side effects may include 
Drugi neželeni učinki lahko vključujejo
The decreases in white blood cell (WBC) and neutrophil counts occurred mainly during the first six weeks of therapy, with values remaining relatively stable thereafter. 
Do zmanjšanja koncentracij belih krvničk (WBC) in nevtrofilcev je prišlo predvsem v prvih šestih tednih zdravljenja, zatem pa so vrednosti ostale relativno stabilne.
Healthcare professionals are asked to report any suspected adverse reactionsvia the national reporting system listed in Appendix V. 
Od zdravstvenih delavcev se zahteva, da poročajo o katerem koli domnevnem neželenem učinku zdravila na nacionalni center za poročanje, ki je naveden v Prilogi V.
Dermatofibrosarcoma protuberans (DFSP). 
- s protuberantnim dermatofibrosarkomom (DFSP).
Imatinib pharmacokinetics have not been specifically studied in elderly. 
Farmakokinetike imatiniba pri starejših niso posebej proučili.
Middlesex, HA1 4HF United Kingdom 
Middlesex, HA1 4HF Velika Britanija
No specific dose recommendation is necessary in elderly. 
Pri starejših niso potrebna posebna priporočila glede odmerjanja.
The safety database for children and adolescents with Ph+ALL is very limited though no new safety concerns have been identified. 
Čeprav je baza podatkov za otroke in mladostnike s Ph+ ALL zelo majhna, zaenkrat niso odkrili nobenih novih pomislekov glede varnosti.
For patients unable to swallow the film-coated tablets, the tablets may be dispersed in a glass of mineral water or apple juice. 
Bolnikom, ki ne morejo pogoltniti filmsko obloženih tablet, lahko tablete raztopimo v kozarcu mineralne vode ali jabolčnega soka.
Chronic phase, newly diagnosed 
Kronična faza, na novo diagnosticirana
- Imatinib Accord is not recommended during pregnancy unless clearly necessary as it may harm your baby. 
- Uporabe zdravila Imatinib Accord v nosečnosti ne priporočamo, če to ni nujno potrebno, saj lahko škoduje vašemu otroku.
Your doctor has prescribed Imatinib Accord because you suffer from a serious condition. 
Zdravnik vam je predpisal zdravilo Imatinib Accord, ker imate resno bolezen.
Your doctor will discuss with you the possible risks of taking Imatinib Accord during pregnancy. 
Zdravnik se bo pogovoril z vami o možnih nevarnostih jemanja zdravila Imatinib Accord v nosečnosti.
Since increased vascularity and propensity for bleeding is a part of the nature and clinical course of GIST, standard practices and procedures for the monitoring and management of haemorrhage in all patients should be applied. 
Ker sta povečana vaskularnost in nagnjenje h krvavitvam del narave in kliničnega poteka GIST, je treba pri vseh bolnikih uporabiti standardne prakse in postopke za spremljanje in zdravljenje krvavitev.
Importantly, 27.7% of patients also achieved a major cytogenetic response, which was complete in 20.4% (confirmed 16%) of patients. 
Pri tem je pomembno, da je 27,7 % bolnikov doseglo tudi pomemben citogenetični odziv, ki je bil pri 20,4 % bolnikov popoln (potrjen pri 16 %).
Major cytogenetic response Complete (Confirmed 
Pomemben citogenetični odziv popoln (potrjen
What Imatinib Accord is and what it is used for What you need to know before you take Imatinib Accord How to take Imatinib Accord Possible side effects 
Kaj je zdravilo Imatinib Accord in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Imatinib Accord Kako jemati zdravilo Imatinib Accord Možni neželeni učinki
5 patients responded, 3 completely and 2 partially. 
Do odziva je prišlo pri 5 bolnikih, pri 3 do popolnega in pri 2 do delnega.
Accord Healthcare Limited Sage House, 319 Pinner Road North Harrow 
Sage House, 319 Pinner Road North Harrow,
While you are taking Imatinib Accord, your doctor will regularly check whether the medicine is working. 
Med jemanjem zdravila Imatinib Accord bo zdravnik redno spremljal, ali zdravilo deluje.
Study 0109 40.5-month data Accelerated phase (n=235) 
Študija 0109 podatki pri 40,5 meseca pospešena faza (n=235)
However, some of these reactions may be serious or life-threatening and several patients with blast crisis died with a complex clinical history of pleural effusion, congestive heart failure and renal failure. 
Vendar so nekatere od teh reakcij lahko resne ali smrtno nevarne.Več bolnikov z blastno krizo je namreč umrlo z zapleteno klinično anamnezo plevralnega izliva, kongestivnega popuščanja srca in ledvične odpovedi.
A further 6DFSP patients treated with imatinib were reported in 5 published case reports, their ages ranging from 18 months to 49 years. 
Nadaljnjih 6 bolnikov z DFSP, zdravljenih z imatinibom, so opisali v 5 publikacijah opisov primera, njihova starost se je gibala med 18 meseci in 49 leti.
Imatinib Accord will only be prescribed to you by a doctor with experience in medicines to treat blood cancers or solid tumours. 
Zdravilo Imatinib Accord vam lahko predpiše samo zdravnik, ki ima izkušnje z zdravili za zdravljenje krvnih rakov in solidnih tumorjev.
The rate ofresponse was also higher in the patients treated at 600 mg (33%) as compared to the patients treated at 400 mg (16%, p=0.0220). 
Stopnja odziva je bila tudi večja pri bolnikih, zdravljenih s 600 mg (33 %), kot pri bolnikih, zdravljenih s 400 mg (16 %, p=0,0220).
In this study 65% of the patients achieved a major cytogenetic response that was complete in 53% (confirmed 43%) of patients (Table 3). 
V tej študiji je 65 % bolnikov doseglo pomemben citogenetični odziv, ki je bil popoln pri 53 % (potrjen pri 43 %) bolnikov (preglednica 3).
Because of known increased risks of bleeding in conjunction with the use of imatinib (e.g. haemorrhage), patients who require anticoagulation should receive low-molecular-weight or standard heparin, instead of coumarin derivatives such as warfarin. 
Zaradi znanega povečanega tveganja za krvavitve v povezavi z uporabo imatiniba (na primer hemoragija) naj bolniki, pri katerih je potrebna antikoagulantna terapija, dobivajo nizkomolekularni ali standardni heparin namesto kumarinskih derivatov, kot je varfarin.
• Do not use this medicine after the expiry date which is stated on the carton and blister after 
• Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in pretisnem omotu poleg oznake “EXP”.
Women of childbearing potential must be advised to use effective contraception during treatment. 
Ženske v rodni dobi Ženskam v rodni dobi je treba svetovati, naj med zdravljenjem uporabljajo učinkovito kontracepcijo.
In patients treated with metoprolol clinical monitoring should be considered. 
Pri bolnikih, ki se zdravijo z metoprololom, je treba razmisliti o kliničnem nadzoru.
They may increase or decrease the effect of Imatinib Accord, either leading to increased side effects or making Imatinib Accord less effective. 
Lahko povečajo ali zmanjšajo učinek zdravila Imatinib Accord in zato bodisi povečajo verjetnost za nastanek neželenih učinkov, bodisi zmanjšajo učinkovitost zdravila Imatinib Accord.
- If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. 
Nosečnost, dojenje in plodnost - Če ste noseči ali dojite, menite, da bi lahko bili noseči ali načrtujete zanositev, se posvetujte z zdravnikom, preden vzamete to zdravilo.
Imatinib did not interfere with the biotransformation of 5-fluorouracil, but it inhibited paclitaxel metabolism as a result of competitive inhibition of CYP2C8 (Ki = 34.7 μM). 
Imatinib ni oviral biotransformacije 5-fluorouracila, je pa zaviral presnovo paklitaksela zaradi kompetitivne inhibicije CYP2C8 (Ki = 34,7 μM).
The percentage of some adverse reactions was higher in the 40 patients in whom the dose was increased to 800 mg daily compared to the population of patients before dose increase (n=551). 
Odstotni delež nekaterih neželenih reakcij je bil večji pri tistih 40 bolnikih, pri katerih je bil odmerek zvečan na 800 mg na dan, kot pri populaciji bolnikov pred zvečanjem odmerka (n=551).
Pharmacokinetics in children and adolescents 
Farmakokinetika pri otrocih in mladostnikih
Imatinib Accord inhibits the growth of these cells in a certain subtype of these diseases. 
Zdravilo Imatinib Accord zavira rast teh celic pri določenih podskupinah teh bolezni.
If you are being treated for CML 
- Če se zdravite zaradi KML
There is no experience in children with CML below 2 years of age and with Ph+ ALL below 1 year of age (see section 5.1). 
Izkušenj pri otrocih s KML, mlajših od 2 let, in pri otrocih s Ph+ALL, mlajših od 1 leta, ni (glejte poglavje 5.1).
The doctor will tell you how many tablets of Imatinib Accord to give to your child. 
Zdravnik vam bo povedal, koliko tablet zdravila Imatinib Accord dajte svojemu otroku.
8 to 10 g (single dose): Vomiting and gastrointestinal pain have been reported. 
Odmerki od 8 do 10 g (enkratni odmerki): Opisovali so bruhanje in bolečine v prebavilih.
This was a population of heavily pretreated patients, as 46% had received prior BMT and 73% a prior multi-agent chemotherapy. 
To je bila skupina že prej močno zdravljenih bolnikov, saj jih je pred začetkom raziskave 46 % prejelo BMT, 73 % pa kemoterapijo z več zdravili.
The yearly rates of progression of any type for Imatinib also decreased over time. 
Tudi letne stopnje kakršnegakoli napredovanja bolezni za zdravilo Imatinib Accord so se sčasoma zmanjševale.
If this applies to you, tell your doctor without taking Imatinib Accord. 
Če to velja za vas, povejte zdravniku in ne jemljite zdravila Imatinib Accord.
The majority of patients who achieved a CCyR developed the CCyR between months 3 and 10 with a median time to response based on the Kaplan-Meier estimate of 5.6 months. 
Večina bolnikov, ki je dosegla popolni citogenetični odziv, ga je dosegla med 3. in 10. mesecem s povprečnim časom do odziva 5,6 meseca glede na Kaplan-Meierjevo oceno.
Renal function should, therefore, be evaluated prior to the start of imatinib therapy and closely monitored during therapy, with particular attention to those patients exhibiting risk factors for renal dysfunction. 
Zato je treba pred začetkom zdravljenja z imatinibom oceniti delovanje ledvic in ga med zdravljenjem natančno spremljati, še posebej pri tistih bolnikih, ki kažejo dejavnike tveganja za ledvično disfunkcijo.
Imatinib Accord is a medicine containing an active substance called imatinib. 
Imatinib Accord je zdravilo, ki vsebuje zdravilno učinkovino z imenom imatinib.
Imatinib Accord inhibits the growth of these cells. 
Zdravilo Imatinib Accord zavira rast teh celic.
Long-term treatment with imatinib may be associated with a clinically significant decline in renal function. 
Dolgotrajno zdravljenje z imatinibom je lahko povezano s klinično pomembnim zmanjšanjem delovanja ledvic.
Imatinib and the N-demethyl metabolite together accounted for about 65% of the circulating radioactivity (AUC(0-48h)). 
Imatinib in N-demetilirani presnovek sta skupaj prispevala okrog 65 % radioaktivnosti v krvi (AUC(048h)).
Ara-C: cytosine arabinoside; CP: cyclophosphamide; DEX: dexamethasone; MTX: methotrexate; 6-MP: 6-mercaptopurine VM26: Teniposide; VCR: vincristine; IDA: idarubicine; i.v. 
Ara-C: citozin arabinozid; CP: ciklofosfamid; DEX: deksametazon; MTX: metotreksat; 6-MP: 6merkaptopurin; VM26: tenipozid; VCR: vinkristin; IDA: idarubicin; i.v.
If anti-ADAMTS13-antibody is elevated in conjunction with low ADAMTS13 activity, treatment with Imatinib Accord should not be resumed. 
V primeru, da je koncentracija protiteles proti ADAMTS13 zvišana, aktivnost ADAMTS13 pa nizka, se zdravljenja z zdravilom Imatinib Accord ne sme nadaljevati.
The safety and efficacy of imatinib in children and adolescents with MDS/MPD, DFSP and HES/CEL aged less than 18 years of age have not been established in clinical trials. 
Varnost in učinkovitost uporabe imatiniba pri otrocih in mladostnikih, ki imajo MDS/MPD, DFSP ali HES/CEL in so stari manj kot 18 let, nista bili dokazani v kliničnih preskušanjih.
Imatinib Accord can help you to fight this condition. 
Zdravilo Imatinib Accord vam lahko pomaga pri premagovanju te bolezni.
Constitutive activation of the PDGF receptor or the Abl protein tyrosine kinases as a consequence of fusion to diverse partner proteins or constitutive production of PDGF have been implicated in the pathogenesis of MDS/MPD, HES/CEL and DFSP. 
Konstitutivna aktivacija receptorja za rastni faktor iz trombocitov ali Abl protein-tirozin-kinaze kot posledica združitve različnih sodelujočih proteinov, ali konstitutivna tvorba PDGF sta vpleteni v patogenezo MDS/MPD, HES/CEL in DFSP.
Increased blood urea nitrogen (BUN) and creatinine were observed in several of these animals. 
Pri mnogih od teh živali sta se zvišala dušik sečnine v krvi (BUN) in kreatinin.
In clinical trials, there was an increased incidence of these events in elderly and those with a prior history of cardiac disease. 
V kliničnih preskušanjih so bili ti učinki pogostejši pri starejših in pri bolnikih z anamnezo bolezni srca.
The increase is approximately 1.5- to 2-fold, corresponding to a 1.5-fold elevation of plasma AGP, to which imatinib binds strongly. 
Gre za približno 1,5 do 2-kratno zvišanje, ki ustreza 1,5-kratnemu zvišanju alfa kislega proteina v plazmi, na katerega se imatinib močno veže.
- if you are allergic to imatinib or any of the other ingredients of this medicine (listed in section 6). 
Ne jemljite zdravila Imatinib Accord - če ste alergični na imatinib ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
An additional four HES patients were found to be FIP1L1-PDGFRα-positive in other 3 published reports. 
FIP1L1PDGFRα pozitivni so bili še štirje bolniki s HES, ki so jih opisovali v drugih 3 objavljenih poročilih.
Packs containing 10, 30, or 90 film-coated tablets. 
Škatle, ki vsebujejo po 10, 30 ali 90 filmsko obloženih tablet.
For adult patients with relapsed or refractory Ph+ALL Imatinib monotherapy at 600 mg/day is safe, effective and can be given until disease progression occurs. 
Za odrasle bolnike z relapsom ali neodzivno Ph+ ALL je zdravilo Imatinib kot monoterapija v odmerku 600 mg/dan varno in učinkovito ter ga lahko prejemajo dokler ne pride do napredovanja bolezni.
This clinical effect was associated with a higher reduction in bcr-abl transcripts in the imatinib-treated patients than in the chemotherapy arm after 2 weeks of therapy (p=0.02). 
Ta klinični učinek je bil povezan z večjim zmanjšanjem količine transkriptov bcrabl pri bolnikih, zdravljenih z imatinibom, kot pri skupini, zdravljeni s kemoterapijo po 2 tednih zdravljenja (p=0,02).
What you need to know before you take Imatinib Accord 
Kaj morate vedeti, preden boste vzeli zdravilo Imatinib Accord
In contrast, there were 165 (29.8%) events in the IFN+Ara-C arm, of which 130 occurred during first-line treatment with IFN+Ara-C. 
Za razliko od tega je bilo v kraku z IFN+Ara-C 165 (29,8 %) dogodkov, od tega se jih je 130 zgodilo v času zdravljenja z IFN+Ara-C kot zdravilom prvega izbora.
The 23 patients enrolled in this registry received imatinib at a median daily dose of 264 mg (range: 100 to 400 mg) for a median duration of 7.2 years (range 0.1 to 12.7 years). 
23 bolnikov, ki so bili vključeni v register, je prejemalo zdravilo imatiniba z mediano dnevnega odmerka 264 mg (v razponu od 100 do 400 mg) in z mediano trajanja zdravljenja 7,2 leti (v razponu od 0,1 do 12,7 leta).
• adult and paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. 
• odraslih in pediatričnih bolnikov s Ph+ KML v kronični fazi po neuspelem zdravljenju z interferonom alfa, ali v pospešeni fazi ali blastni krizi;
The experience with imatinib in patients with MDS/MPD associated with PDGFR gene re-arrangements is very limited (see section 5.1). 
Izkušenj z imatinibom pri bolnikih MDS/MPD v povezavi s preureditvijo genov za PDGFR je malo (glejte poglavje 5.1).
In adults the dose should be reduced from 400 to 300 mg or from 600 to 400 mg, or from 800 mg to 600 mg, and in children and adolescents from 340 to 260 mg/m2/day. 
Pri odraslih je treba zmanjšati odmerek s 400 na 300 mg ali s 600 na 400 mg ali z 800 na 600 mg, pri otrocih in mladostnikih pa s 340 na 260 mg/m2/dan.
Packs containing 20, 60, 120 or 180 film-coated tablets. 
Škatle, ki vsebujejo po 20, 60, 120 ali 180 filmsko obloženih tablet.
Do not stop taking Imatinib Accord unless your doctor tells you to. 
Ne prenehajte jemati zdravila Imatinib Accord, razen če vam tako naroči zdravnik.
What Imatinib Accord is and what it is used for 
Kaj je zdravilo Imatinib Accord in za kaj ga uporabljamo
The high rate of CHR is accompanied by the development of a completecytogenetic response (CCyR) of 65% which is comparable to the results observed in adults. 
Ob veliki stopnji popolnega hematološkega odziva je prišlo tudi do popolnega citogenetičnega odziva (CCyR) v 65 %, kar je primerljivo z zabeleženimi rezultati pri odraslih.